

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

2A03/2019 UK without DTT

	PBL				T-cells				B-cells			
Total distributed	6	6	6	6	13	13	13	13	15	15	15	15
Total submitted	6	6	6	6	13	13	13	13	15	15	15	15
Not Tested	1	1	1	1	1	1	1	1	4	5	5	5
Negative	5	5	5	5	12	12	12	12	6	7	9	10
Positive	-	-	-	-	-	-	-	-	5	3	1	-
% Negative	100	100	100	100	100	100	100	100	54.5	70	90	100
% Positive	-	-	-	-	-	-	-	-	45.5	30	10	-
Consensus	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	-	-	Negative	Negative
Unacceptable	-	-	-	-	-	-	-	-	-	-	Positive	-
Number acceptable	5	5	5	5	12	12	12	12	-	-	9	10
Number unacceptable	0	0	0	0	0	0	0	0	-	-	1	0
Assessed ☒	☒	☒	☒	☒	☒	☒	☒	☒	☒	☒	☒	☒
Comments												

Lab	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Received	Tested	PBL Assessment	T-cell Assessment	B-cell Assessment
9	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	17/07/2019	18/07/2019	100%	100%	100%
11	NT	NT	NT	NT	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	17/07/2019	18/07/2019	Not assessed	100%	100%
12	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	NT	NT	NT	17/07/2019	17/07/2019	100%	100%	Not assessed
15													17/07/2019	17/07/2019	Not assessed	Not assessed	Not assessed
20	Negative	Negative	Negative	Negative					Negative	Negative	Negative	Negative	17/07/2019	18/07/2019	100%	Not assessed	100%
23					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	17/07/2019	17/07/2019	Not assessed	100%	100%
24					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	17/07/2019	17/07/2019	Not assessed	100%	100%
25					Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	17/07/2019	17/07/2019	Not assessed	100%	100%
28					Negative	Negative	Negative	Negative	NT	NT	NT	NT	17/07/2019	17/07/2019	Not assessed	100%	Not assessed
34													17/07/2019	17/07/2019	Not assessed	Not assessed	Not assessed
38	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	Negative	17/07/2019	17/07/2019	100%	100%	50%
39													17/07/2019	17/07/2019	Not assessed	Not assessed	Not assessed
41					NT	NT	NT	NT	NT	NT	NT	NT	0000-00-00	0000-00-00	Not assessed	Not assessed	Not assessed
42	Negative	Negative	Negative	Negative					Negative	Negative	Negative	Negative	17/07/2019	18/07/2019	100%	Not assessed	100%
45					Negative	Negative	Negative	Negative	NT	NT	NT	NT	17/07/2019	17/07/2019	Not assessed	100%	Not assessed
51					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	17/07/2019	17/07/2019	Not assessed	100%	100%
54					Negative	Negative	Negative	Negative	NT	NT	NT	NT	17/07/2019	18/07/2019	Not assessed	100%	Not assessed
58					Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	17/07/2019	17/07/2019	Not assessed	100%	100%

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

2A03/2019 UK without DTT

Lab	PBL Reaction strength				T-cell Reaction strength				B-cell Reaction strength				Viability		
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	PBL	T-cell	B-cell
9	0	0	0	0	0	0	0	0	0	0	0	0	80	80	80
11					1	1	1	1	2	1	1	1		95	75
12									75%				95	95	50
15														90	90
20	1	1	1	1					1	1	1	1	90	0	85
23					1	1	1	1	1	2	1	2		90	80
24					20%	10%	20%	10%	30%	30%	30%	30%		90	90
25					1	1	1	1	6	4	2	2		99	99
28					1	1	1	1						100	70
34														99	75
38	1	1	1	1	1	1	1	1	8	4	4	1	95	100	95
39														99	99
41															
42	<10%	<10%	<10%	<10%					<10%	<10%	<10%	<10%	95		70
45					1	1	1	1						95	30
51					0	0	0	0	0	0	0	0	95	95	90
54					0	0	0	0						100	
58					5	5	5	5	80	40	25	25	0	95	75

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

2A03/2019 UK with DTT														
	PBL				T-cells				B-cells					
Total distributed	6	6	6	6	15	15	15	15	17	17	17	17		
Total submitted	6	6	6	6	15	15	15	15	17	17	17	17		
Not Tested	1	1	1	1	2	1	2	2	7	6	7	7		
Negative	5	5	5	5	13	14	13	13	10	11	10	10		
% Negative	100	100	100	100	100	100	100	100	100	100	100	100		
Consensus	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		
Unacceptable	-	-	-	-	-	-	-	-	-	-	-	-		
Number acceptable	5	5	5	5	13	14	13	13	10	11	10	10		
Number unacceptable	0	0	0	0	0	0	0	0	0	0	0	0		
Assessed ☒	☒	☒	☒	☒	☒	☒	☒	☒	☒	☒	☒	☒		
Comments														

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

2A03/2019 UK with DTT

Lab	PBL Reaction strength				T-cell Reaction strength				B-cell Reaction strength				Viability		
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	PBL	T-cell	B-cell
9	0	0	0	0	0	0	0	0	0	0	0	0	80	80	80
11					1	1	1	1		1	1	1		95	75
12													95	95	50
15					0	0	0	0	0	0	0	0		90	90
20	1	1	1	1					1	1	1	1	90	0	85
23														90	80
24					N/A	30%	N/A	N/A	N/A	30%	N/A	N/A		90	90
25					1	1	1	1	1	1	1	1		99	99
28					1	1	1	1						100	70
34														99	75
38	1	1	1	1	1	1	1	1	1	1	1	1	95	100	95
39														99	99
41															
42	<10%	<10%	<10%	<10%					<10%	<10%	<10%	<10%	95		70
45					1	1	1	1						95	30
51					0	0	0	0	0	0	0	0	95	95	90
54					0	0	0	0						100	
58					5	5	5	5					0	95	75

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

2A04/2019 UK without DTT

2A04/2019 OR without DTT																	
	PBL				T-cells				B-cells								
Total distributed	6	6	6	6	13	13	13	13	15	15	15	15					
Total submitted	6	6	6	6	13	13	13	13	15	15	15	15					
Not Tested	2	2	2	2	2	2	2	2	3	3	3	3					
Negative	4	4	4	4	11	11	11	11	10	11	11	12					
Positive	-	-	-	-	-	-	-	-	2	1	1	-					
% Negative	100	100	100	100	100	100	100	100	83.3	91.7	91.7	100					
% Positive	-	-	-	-	-	-	-	-	16.7	8.3	8.3	-					
Consensus	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative					
Unacceptable	-	-	-	-	-	-	-	-	Positive	Positive	Positive	-					
Number acceptable	4	4	4	4	11	11	11	11	10	11	11	12					
Number unacceptable	0	0	0	0	0	0	0	0	2	1	1	0					
Assessed ☒	☒	☒	☒	☒	☒	☒	☒	☒	☒	☒	☒	☒					
Comments																	
Lab	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Received	Tested	PBL	T-cell	B-cell
9	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	17/07/2019	18/07/2019	100%	100%	100%
11	NT	NT	NT	NT	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	17/07/2019	18/07/2019	Not assessed	100%	100%
12	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	17/07/2019	17/07/2019	100%	100%	100%
15													17/07/2019	18/07/2019	Not assessed	Not assessed	Not assessed
20	Negative	Negative	Negative	Negative					Negative	Negative	Negative	Negative	17/07/2019	18/07/2019	100%	Not assessed	100%
23					Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	17/07/2019	17/07/2019	Not assessed	100%	75%
24					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	17/07/2019	17/07/2019	Not assessed	100%	100%
25					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	17/07/2019	17/07/2019	Not assessed	100%	75%
28					Negative	Negative	Negative	Negative	NT	NT	NT	NT	17/07/2019	17/07/2019	Not assessed	100%	Not assessed
34													17/07/2019	17/07/2019	Not assessed	Not assessed	Not assessed
38	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	17/07/2019	0000-00-00	Not assessed	Not assessed	Not assessed
39													17/07/2019	17/07/2019	Not assessed	Not assessed	Not assessed
41					NT	NT	NT	NT	NT	NT	NT	NT	0000-00-00	0000-00-00	Not assessed	Not assessed	Not assessed
42	Negative	Negative	Negative	Negative					Negative	Negative	Negative	Negative	17/07/2019	18/07/2019	100%	Not assessed	100%
45					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	17/07/2019	17/07/2019	Not assessed	100%	75%
51					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	17/07/2019	17/07/2019	Not assessed	100%	100%
54					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	17/07/2019	18/07/2019	Not assessed	100%	75%
58					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	17/07/2019	17/07/2019	Not assessed	100%	100%

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

2A04/2019 UK without DTT

Lab	PBL Reaction strength				T-cell Reaction strength				B-cell Reaction strength				Viability		
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	PBL	T-cell	B-cell
9	0	0	0	0	0	0	0	0	0	0	0	0	90	90	90
11					1	1	1	1	1	1	1	1		90	80
12													95	95	95
15														99	99
20	1	1	1	1					1	1	1	1	90	0	90
23					2	1	2	1	2	2	4	2		90	80
24					10%	10%	10%	10%	30%	30%	40%	30%		90	90
25					1	1	1	1	4	2	2	2		99	99
28					1	1	1	1						99	70
34														99	75
38													90	99	98
39														99	99
41															
42	<10%	<10%	<10%	<10%					<10%	<10%	<10%	<10%	95		90
45					1	1	1	1	4	1	1	1		95	90
51					0	0	0	0	0	0	0	0	95	95	90
54					<10%	<10%	<10%	<10%	30%	40%	30%	20%	0	95	85
58					5	5	5	5	10	5	5	5	0	95	90

2A04/2019 UK with DTT

Effective Date 09/04/18

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

2A04/2019 UK with DTT

Lab	PBL Reaction strength				T-cell Reaction strength				B-cell Reaction strength				Viability		
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	PBL	T-cell	B-cell
9	0	0	0	0	0	0	0	0	0	0	0	0	90	90	90
11					1	1	1	1	1	1	1	1	90	90	80
12													95	95	95
15					0	0	0	0	0	0	0	0	99	99	99
20	1	1	1	1					1	1	1	1	90	0	90
23													90	80	
24					N/A	20%	20%	N/A	N/A	30%	30%	30%	90	90	
25					1	1	1	1	1	1	1	1	99	99	
28					1	1	1	1					99	70	
34													99	75	
38													90	99	98
39													99	99	
41															
42	<10%	<10%	<10%	<10%					<10%	<10%	<10%	<10%	95		90
45					1	1	1	1	1	1	1	1		95	90
51					0	0	0	0	0	0	0	0	95	95	90
54					<10%	<10%	<10%	<10%	15%	20%	30%	15%	0	95	85
58					5	5	5	5	5	5	5	5	0	95	90